Your industry news - first
New agreement delivers surface disinfection to global public health commodity procurement programs
AREV Nanotech Brands, a publicly traded life science enterprise, and sanitising and disinfecting company Germinator, have entered into a definitive agreement to provide the Genesis hypochlorous acid (HOCl) platform of surface disinfection to global public health commodity procurement programs to aid refugees and Internally Displaced Persons throughout Central and South America, Africa, eastern Europe, and Asia.
Refugee and IDP camps continue to experience a profound health crisis related to Covid-19 as well as drug-resistant variants of other infectious diseases, such as Extensively Drug-Resistant Tuberculosis (XDR TB). The distribution partnership will provide refugee and IDP populations with ongoing access to surface disinfectant treatments and air filtration systems to help curtail the transmission of contagious pathogens.
Programs with geographic presence subject to this agreement include: the World Health Organisation, the International Red Cross and Red Crescent Movement, Médecins Sans Frontières, Partners In Health, The US President's Emergency Plan for AIDS Relief (PEPFAR), Supply Chain Management System, John Snow, United Nations High Commissioner for Refugees, International Organisation for Migration, World Food Programme, International Rescue Committee, Danish Refugee Council, Oxfam, Mercy Corps, Catholic Relief Services, and others.
"This collaboration to expand the utility of the Genesis HOCl disinfection solution into the public health venues that are at greatest risk for highly contagious infectious disease will provide demonstratable solutions essential to vulnerable populations," says Jeff Gill, founder and CEO of Germinator.
"There are over 70 million people subject to significant overcrowding in more than 100 IDP and refugee camps around the world. These camps are being administrated by an unprecedented number of organisations that have continued to express their deepening concerns regarding current overcapacities as it relates to remediating the potential for new epidemics emerging during the current public health crisis."
The US Agency for International Development (USAID) of the Department of State has stressed that the pandemic is one of the greatest health challenges the world has ever faced, stating: "To beat Covid-19 in the US and abroad, keep Americans safe, rebuild our economy, and curb the emergence of variants, we must fight it everywhere it exists."
USAID is currently providing disinfection supplies to countries where Covid-19 has been identified as epidemiologically significant.
Throughout this partnership, AREV has been assigned distribution rights to Germinator's platform of disinfecting products, including electrostatic sprayers and drone distribution that dispense Germinator's disinfectant solution. Germinator's HOCl disinfecting solution is on the EPA N List of products determined to meet the criteria for use against Covid-19 and other microbes. The solution is a virucide against a wide range of bacteria, including Staphylococcus aureus, MRSA, Salmonella enterica, and Pseudomonas aeruginosa, as well as viruses including norovirus, rotavirus, and adenovirus on hard, non-porous, environmental surfaces. It meets the Association of Official Agricultural Chemists (AOAC) germicidal spray standards for Hospital-Grade Disinfection.
"Refugees and migrants live and work in often-harsh conditions with inadequate access to health, housing, water, sanitation and other basic services," notes WHO director-general Dr Tedros Adhanom Ghebreyesus.
"It is vital for all countries to reduce barriers that prevent refugees and migrants from obtaining health care, and to include them in national health policies."
Chad S. Johnson, special counsel to AREV and strategic policy advisor to Germinator, says of the initiative:
"While global health leaders are working to address Covid-19 among key populations in resource-challenged nations, ongoing remediation of deadly pathogens other than Covid-19 is imperative for the prevention of future catastrophic pandemics, which often begin within vulnerable, transient populations.
"While cases of drug-resistant infections, including HIV and TB, currently remain low in developed countries, the likelihood of rapid spread continues to grow as population size continues to increase."
24th June 2021